Why Veeva Systems Shares Are Diving Friday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 31 2024
0mins
Source: Benzinga
- Financial Performance: Veeva Systems Inc. reported strong first-quarter FY25 results with a 24% increase in revenue to $650.3 million, surpassing expectations.
- Operating Income and EPS: Adjusted operating income grew by 66% year-over-year to $260.9 million, and adjusted EPS was $1.50, beating the consensus estimate.
- Cash Position: As of April-end, Veeva Systems had $1.20 billion in cash and equivalents along with short-term investments of $3.6 billion.
- Outlook: The company expects slightly lower revenue for the second quarter compared to estimates but reiterated its adjusted EPS and operating income guidance for FY25.
- Stock Performance: VEEV shares were down by 9.21% at $176.02 following the earnings report, impacting ETFs like First Trust Nasdaq Lux Digital Health Solutions ETF EKG and Sterling Capital Focus Equity ETF LCG.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VEEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VEEV
Wall Street analysts forecast VEEV stock price to rise
23 Analyst Rating
16 Buy
6 Hold
1 Sell
Moderate Buy
Current: 159.540
Low
222.00
Averages
317.10
High
380.00
Current: 159.540
Low
222.00
Averages
317.10
High
380.00
About VEEV
Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. It offers span cloud software, data and business consulting and is designed to meet the needs of its customers and strategic business functions from research and development (R&D) through commercialization. Its product categories include Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Quality Cloud unifies applications, processes and partners across content management, training, quality management, assurance and control lab solutions on the Veeva Vault platform. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. It owns Ostro, a brand engagement platform for life sciences that gives an artificial intelligence (AI)-driven chat experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Burry Increases Stakes in Adobe and Veeva Stocks
- Increased Adobe Holdings: Burry purchased Adobe shares at $199.59 each, despite a nearly 7% drop post-earnings report, indicating strong long-term profitability with a gross margin near an all-time high of 89.4%.
- Investment in Veeva: He bought Veeva stock at $159.05, which has declined nearly 30% year-to-date, yet its price-to-earnings and price-to-sales ratios are significantly below historical levels, suggesting market undervaluation amid strong adoption of its cloud software in the pharmaceutical sector.
- Market Sentiment Analysis: On Stocktwits, retail sentiment for Adobe remains ‘extremely bullish’, while Veeva is ‘bearish’, reflecting divergent investor expectations that could influence future market performance.
- Emergence of Value Stocks: Burry noted on his Substack that the market is witnessing a bifurcation between extreme value and extreme overvaluation, suggesting that some undervalued U.S. stocks may perform well during a market crash, highlighting a focus on value investing.
See More
UCB Partners with Veeva to Enhance Safety Management
- Unified Safety Management: UCB standardizes its global safety processes using Veeva Safety Suite, aiming to enhance operational efficiency and scalability, thereby accelerating case processing and optimizing regulatory submissions.
- Automation Drives Efficiency: By leveraging Veeva's automation tools, UCB promotes contactless case handling, ensuring higher transparency and coordination in safety data management, which enhances patient medication safety.
- Enhanced Data Analysis Capabilities: The introduction of Veeva Safety Workbench enables more efficient data analysis, supporting rapid and scalable report generation, further improving UCB's performance in global compliance.
- Strategic Partnership Outlook: UCB's strategic collaboration with Veeva not only simplifies pharmacovigilance activities but also drives advanced automation through standardized processes, ensuring that patients receive safe and effective medications.
See More
UCB Partners with Veeva to Enhance Safety Operations
- Global Safety Unification: UCB's collaboration with Veeva Safety Suite aims to enhance operational efficiency in global safety operations through a unified platform, thereby accelerating adverse event processing, improving regulatory compliance, and enhancing patient safety.
- Process Automation Optimization: UCB will leverage Veeva Safety's automation capabilities to streamline the reception, processing, and submission of adverse events, which is expected to significantly improve operational efficiency and reduce human errors, ensuring data accuracy and reliability.
- Enhanced Data Analysis Capability: With advanced data analytics from Veeva Safety Workbench, UCB can quickly generate scalable reports, further improving its ability to detect safety signals, thus enhancing the company's competitiveness in the drug safety sector.
- Strategic Partnership Outlook: The strategic partnership between UCB and Veeva not only aids in standardizing global pharmacovigilance but also drives innovation capabilities within the biopharmaceutical industry, ensuring the delivery of safe and effective medications to patients.
See More
UCB Unifies Global Safety Operations with Veeva Safety Suite
- Platform Integration: UCB is unifying its global safety operations with Veeva Safety Suite to enhance operational efficiency and scalability, which is expected to accelerate case processing and simplify reporting to regulatory authorities.
- Process Automation: By utilizing Veeva Safety Suite, UCB will automate the reception, processing, and reporting of adverse events, thereby increasing data processing speed and ensuring the reliability of information.
- Enhanced Data Analysis: Veeva Safety Workbench will provide advanced data analysis capabilities to support rapid and scalable report generation, further improving UCB's compliance in global pharmacovigilance.
- Strategic Partnership Outlook: The strategic collaboration between UCB and Veeva not only lays the groundwork for global pharmacovigilance but also enhances the company's competitiveness in drug safety through a unified safety management platform.
See More
UCB Partners with Veeva to Enhance Safety Operations Efficiency
- Global Safety Operations Unification: UCB is unifying its global safety operations with Veeva Safety Suite to enhance operational efficiency and scale, thereby accelerating case processing and strengthening regulatory oversight.
- Automation Transformation: By adopting Veeva Safety Suite's unified platform for end-to-end safety management, UCB is driving low-touch case processing through automation, ensuring a single source of truth for safety data and enhancing global compliance.
- Enhanced Data Analysis Capabilities: Veeva Safety Workbench will enable advanced data analysis for fast, scalable reporting, while Veeva Safety Signal will automate signal detection, improving visibility and alignment across the organization.
- Strategic Partnership Significance: The strategic partnership between UCB and Veeva not only simplifies the global pharmacovigilance function but also drives advanced automation through standardized processes, ensuring the delivery of safe and effective medicines to patients.
See More
UCB Partners with Veeva to Enhance Safety Operations Efficiency
- Global Safety Operations Unification: UCB is unifying its global safety operations on a single platform with Veeva Safety Suite, which is expected to accelerate case processing and enhance regulatory oversight, significantly improving operational efficiency.
- Automation-Driven Transformation: UCB plans to leverage Veeva Safety Suite's automation capabilities to drive low-touch case processing, enhancing efficiency in global and local workflows while ensuring a single source of truth for safety data.
- Data Analysis and Signal Detection: Veeva Safety Workbench will enable fast, scalable reporting, while Veeva Safety Signal will automate signal detection, enhancing visibility and alignment across the organization, thereby improving drug safety monitoring capabilities.
- Compliance and Automation Enhancement: The infrastructure built by UCB through Veeva Safety Suite will simplify and standardize its global pharmacovigilance function, enhancing global compliance and driving advanced automation to ensure safe and effective medicines for patients.
See More
Burry Increases Stakes in Adobe and Veeva Stocks
- Increased Adobe Holdings: Burry purchased Adobe shares at $199.59 each, despite a nearly 7% drop post-earnings report, indicating strong long-term profitability with a gross margin near an all-time high of 89.4%.
- Investment in Veeva: He bought Veeva stock at $159.05, which has declined nearly 30% year-to-date, yet its price-to-earnings and price-to-sales ratios are significantly below historical levels, suggesting market undervaluation amid strong adoption of its cloud software in the pharmaceutical sector.
- Market Sentiment Analysis: On Stocktwits, retail sentiment for Adobe remains ‘extremely bullish’, while Veeva is ‘bearish’, reflecting divergent investor expectations that could influence future market performance.
- Emergence of Value Stocks: Burry noted on his Substack that the market is witnessing a bifurcation between extreme value and extreme overvaluation, suggesting that some undervalued U.S. stocks may perform well during a market crash, highlighting a focus on value investing.
See More
UCB Partners with Veeva to Enhance Safety Management
- Unified Safety Management: UCB standardizes its global safety processes using Veeva Safety Suite, aiming to enhance operational efficiency and scalability, thereby accelerating case processing and optimizing regulatory submissions.
- Automation Drives Efficiency: By leveraging Veeva's automation tools, UCB promotes contactless case handling, ensuring higher transparency and coordination in safety data management, which enhances patient medication safety.
- Enhanced Data Analysis Capabilities: The introduction of Veeva Safety Workbench enables more efficient data analysis, supporting rapid and scalable report generation, further improving UCB's performance in global compliance.
- Strategic Partnership Outlook: UCB's strategic collaboration with Veeva not only simplifies pharmacovigilance activities but also drives advanced automation through standardized processes, ensuring that patients receive safe and effective medications.
See More
UCB Partners with Veeva to Enhance Safety Operations
- Global Safety Unification: UCB's collaboration with Veeva Safety Suite aims to enhance operational efficiency in global safety operations through a unified platform, thereby accelerating adverse event processing, improving regulatory compliance, and enhancing patient safety.
- Process Automation Optimization: UCB will leverage Veeva Safety's automation capabilities to streamline the reception, processing, and submission of adverse events, which is expected to significantly improve operational efficiency and reduce human errors, ensuring data accuracy and reliability.
- Enhanced Data Analysis Capability: With advanced data analytics from Veeva Safety Workbench, UCB can quickly generate scalable reports, further improving its ability to detect safety signals, thus enhancing the company's competitiveness in the drug safety sector.
- Strategic Partnership Outlook: The strategic partnership between UCB and Veeva not only aids in standardizing global pharmacovigilance but also drives innovation capabilities within the biopharmaceutical industry, ensuring the delivery of safe and effective medications to patients.
See More
UCB Unifies Global Safety Operations with Veeva Safety Suite
- Platform Integration: UCB is unifying its global safety operations with Veeva Safety Suite to enhance operational efficiency and scalability, which is expected to accelerate case processing and simplify reporting to regulatory authorities.
- Process Automation: By utilizing Veeva Safety Suite, UCB will automate the reception, processing, and reporting of adverse events, thereby increasing data processing speed and ensuring the reliability of information.
- Enhanced Data Analysis: Veeva Safety Workbench will provide advanced data analysis capabilities to support rapid and scalable report generation, further improving UCB's compliance in global pharmacovigilance.
- Strategic Partnership Outlook: The strategic collaboration between UCB and Veeva not only lays the groundwork for global pharmacovigilance but also enhances the company's competitiveness in drug safety through a unified safety management platform.
See More
UCB Partners with Veeva to Enhance Safety Operations Efficiency
- Global Safety Operations Unification: UCB is unifying its global safety operations with Veeva Safety Suite to enhance operational efficiency and scale, thereby accelerating case processing and strengthening regulatory oversight.
- Automation Transformation: By adopting Veeva Safety Suite's unified platform for end-to-end safety management, UCB is driving low-touch case processing through automation, ensuring a single source of truth for safety data and enhancing global compliance.
- Enhanced Data Analysis Capabilities: Veeva Safety Workbench will enable advanced data analysis for fast, scalable reporting, while Veeva Safety Signal will automate signal detection, improving visibility and alignment across the organization.
- Strategic Partnership Significance: The strategic partnership between UCB and Veeva not only simplifies the global pharmacovigilance function but also drives advanced automation through standardized processes, ensuring the delivery of safe and effective medicines to patients.
See More
UCB Partners with Veeva to Enhance Safety Operations Efficiency
- Global Safety Operations Unification: UCB is unifying its global safety operations on a single platform with Veeva Safety Suite, which is expected to accelerate case processing and enhance regulatory oversight, significantly improving operational efficiency.
- Automation-Driven Transformation: UCB plans to leverage Veeva Safety Suite's automation capabilities to drive low-touch case processing, enhancing efficiency in global and local workflows while ensuring a single source of truth for safety data.
- Data Analysis and Signal Detection: Veeva Safety Workbench will enable fast, scalable reporting, while Veeva Safety Signal will automate signal detection, enhancing visibility and alignment across the organization, thereby improving drug safety monitoring capabilities.
- Compliance and Automation Enhancement: The infrastructure built by UCB through Veeva Safety Suite will simplify and standardize its global pharmacovigilance function, enhancing global compliance and driving advanced automation to ensure safe and effective medicines for patients.
See More
